Lexaria's Second GLP-1 Human Pilot Study Shows Zero Adverse Events in DehydraTECH-processed Rybelsus(R) Oral CapsulesAccesswire • 08/29/24
Lexaria Receives New Patents For Antiviral Drug Delivery and for Treating EpilepsyAccesswire • 07/08/24
Lexaria Announces New Research Program to Evaluate Mode of Action and Performance of DehydraTECH-GLP-1 DrugsAccesswire • 05/06/24